A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Keshav, Satish ^a   Vaňásek, Tomáš ^b   Niv, Yaron ^c   Petryka, Robert ^d   Howaldt, Stephanie ^e   Bafutto, Mauro ^f   Rácz, István ^g   Hetzel, David ^h   Nielsen, Ole Haagen ⁱ   Vermeire, Séverine ^j   Reinisch, Walter ^k   Karlén, Per ^l   Schreiber, Stefan ^m   Schall, Thomas J ⁿ   Bekker, Pirow ⁿ  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Hepato Gastroenterologie HK   (Czech Republic)

^c RABIN MEDICAL CENTER   (Israel)

^d NZOZ Centrum Medyczne   (Poland)

^e Klinik fur Innere Medizin   (Germany)

^f Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda   (Brazil)

^g Petz Aladar Univ Teach Hosp 9024   (Hungary)

^h ROYAL ADELAIDE HOSPITAL   (Australia)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l KAROLINSKA INSTITUTE   (Sweden)

^m UNIVERSITY OF KIEL   (Germany)

ⁿ ChemoCentryx Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CCX 282B; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; UNCLASSIFIED DRUG; VERCIRNON;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CELL MOVEMENT; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; INTESTINES; MALE; MIDDLE AGED; ODDS RATIO; RECEPTORS, CCR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84875195096     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060094     Document Type: Article

References (20)

1. Farmer RG, Hawk WA, Turnbull RB Jr, (1975) Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 68: 627-635.
2. Charo IF, Ransohoff RM, (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-21.
3. Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, et al. (1999) Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 190: 1241-1256.
4. Zaballos A, Gutierrez J, Varona R, Ardavin C, Márquez G, (1999) Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162: 5671.
5. Marsal J, Svensson M, Ericsson A, Iranpour AH, Carramolino L, et al. (2002) Involvement of CCL25 (TECK) in the generation of the murine small-intestineal CD8αα+CD3+ intraepithelial lymphocyte compartment. Eur J Immunol 32: 3488-3497.
6. Svensson M, Marsal J, Ericsson A, Carramolino L, Brodén T, et al. (2002) CCL25 mediates the localization of recently activated CD8αβ+ lymphocytes to the small-intestinal mucosa. J Clin Invest 110: 1113-1121.
7. Pabst O, Ohl L, Wendland M, Wurbel MA, Kremmer E, et al. (2004) Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med 199: 411-416.
8. Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, et al. (2007) CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc Natl Acad Sci USA 104: 6347-6352.
9. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, et al. (2010) Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 335: 65-69.
10. Best WR, Becktel JM, Singleton JW, Kern F, (1976) Development of a Crohn's disease activity index. Gastroenterology 70: 439-444.
11. Mary JY, Modigliani R, (1989) Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study. Gut 30: 983-989.
12. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, et al. (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122: 512-530.
13. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, et al. (2000) The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 165: 5069-5076.
14. Papadakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, et al. (2001) CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 21: 246-254.
15. Walters MJ, Berahovich R, Wang Y, Wei Z, Ungashe S, et al. (2008) Presence of CCR9 and its ligand CCL25/TECK in the colon: scientific rationale for the use of CCR9 small molecule antagonist CCX282-B in colonic disorders. Gut 57 (Suppl II): A39 (OP184).
16. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925.
17. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132: 1672-1683.
18. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, et al. (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238.
19. Hanauer SB, Sandborn WJ, Rutgeers P, Fedorak RN, Lukas M, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333.
20. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, et al. (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374; 1617-1625.